<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00746031</url>
  </required_header>
  <id_info>
    <org_study_id>REC number 08/MRE00/30</org_study_id>
    <nct_id>NCT00746031</nct_id>
  </id_info>
  <brief_title>Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids</brief_title>
  <official_title>Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibroids are present in up to 80% of women of reproductive age. Associated heavy menstrual
      bleeding is often an indication for surgery. At present there are no long-term medical
      treatments for fibroids. There is an unmet need for a pharmacologic agent able to reduce
      excessive bleeding and other symptoms associated with increased uterine volume, which could
      prevent or significantly delay surgery without causing significant unwanted hypoestrogenic
      side effects and allow preservation of fertility.

      The purpose of this study is to investigate and validate novel MR imaging as a non-invasive
      biomarker for monitoring responses to medical interventions aimed at reduction of excessive
      menstrual bleeding and decrease in uterine/ fibroid volume. MR imaging is non-invasive, does
      not involve ionizing radiation and new techniques have the potential to resolve tissue detail
      to near cellular level.

      The investigators are aiming to establish the feasibility and reproducibility of novel MR
      imaging techniques in the evaluation of treatment response in women with fibroids and to
      provide mechanistic information on whether the reduction in blood flow of uterine/fibroid
      vasculature in the shrinkage of fibroids is dependent upon subjects being hypoestrogenic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uterine and fibroid volume</measure>
    <time_frame>2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uterine vascular perfusion, vasculature and extracellular matrix (ECM)content of fibroids.</measure>
    <time_frame>2010</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Fibroid</condition>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GnRH analogue-Zoladex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GnRH antagonist plus GnRH analogue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH analogue (Zoladex)</intervention_name>
    <description>3.6mg subcutaneous implant. Monthly doses x 3.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH antagonist-Cetrorelix</intervention_name>
    <description>Subcutaneous injection 3mg x3 over 7 days</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Cetrotide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age&gt;18 years

          -  Scheduled for hysterectomy with a fibroid uterus

          -  At least one intramural non-pedunculated, submucosal or subserous fibroid(&gt;2cm) or
             multiple small fibroids (uterine volume&gt;200cm3)

          -  Ability to understand and willingness to sign consent form

          -  Normal smear within 3 years

        Exclusion criteria:

          -  Pregnant or lactating

          -  Contra indication to MRI

          -  Unable to tolerate supine position

          -  Diabetes and/or renal or hepatic impairment

          -  Contra indication to any of the study medications including gadolinium, MRI contrast
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HILARY OD CRITCHLEY, MBChB;MD;FRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Edinburgh/ Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <last_update_submitted>October 22, 2010</last_update_submitted>
  <last_update_submitted_qc>October 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>PROFESSOR HILARY OD CRITCHLEY</name_title>
    <organization>UNIVERSITY OF EDINBURGH</organization>
  </responsible_party>
  <keyword>MTI</keyword>
  <keyword>Fibroids</keyword>
  <keyword>Novel</keyword>
  <keyword>MR imaging</keyword>
  <keyword>techniques</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
    <mesh_term>Cetrorelix</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

